Sequence- and target-independent angiogenesis suppression by siRNA via TLR3

By M. Kleinman, Kiyoshi Yamada, A. Takeda, V. Chandrasekaran, M. Nozaki, J. Baffi, R. Albuquerque, S. Yamasaki, M. Itaya, Yuzhen Pan and 12 more. Nature, 2008

948 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/0208607c0b88b42f978c69c859e44c48b76e1473

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. John J. Rossi
2. Dan R. Littman
3. J. Nemunaitis
4. M. Chong
5. K. Karikó
6. T. Malek
7. I. Castro

In Molecular Biology

1. John S. Mattick
2. Marcel E. Dinger
3. Tim R. Mercer
4. Ryan J. Taft
5. Ken C. Pang
6. John C. Burnett
7. John J. Rossi
8. M. Manoharan

Citations in the corpus

• Lipid-like materials for low-dose, in vivo gene silencing (2010, background): “In some applications, effective delivery of naked siRNAs, without a carrier, may be possible (6, 7).”
• Non‐coding RNAs: regulators of disease (2010, background): “Like gene therapy, however, RNA therapeutics face considerable hurdles, including development of reliable delivery systems, dosage regimes and techniques to ameliorate offtarget effects [210,211].”
• The current state and future directions of RNAi-based therapeutics (2019, neutral): “(8) A guide strand (antisense) is selected(295) and loaded into Ago1–Ago4 and”
• Delivery of siRNA Therapeutics: Barriers and Carriers (2010, background): “This study further showed that this general siRNA-mediated suppression of neovascularization was due to nonspecifi cs timulation of the cell surface Toll-like receptor TLR3 pathway, its adaptor TRIF, and induction of interferon-gamma and interleukin-12 ( 94 ).”